Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Common Equity (2023 - 2025)

Kura Oncology (KURA) has disclosed Common Equity for 3 consecutive years, with $174.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 57.9% to $174.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $174.1 million through Dec 2025, down 57.9% year-over-year, with the annual reading at $174.1 million for FY2025, 57.9% down from the prior year.
  • Common Equity for Q4 2025 was $174.1 million at Kura Oncology, down from $242.5 million in the prior quarter.
  • The five-year high for Common Equity was $505.1 million in Q1 2024, with the low at $174.1 million in Q4 2025.
  • Average Common Equity over 3 years is $381.4 million, with a median of $405.5 million recorded in 2023.
  • The sharpest move saw Common Equity increased 27.81% in 2024, then plummeted 57.9% in 2025.
  • Over 3 years, Common Equity stood at $397.3 million in 2023, then increased by 4.12% to $413.6 million in 2024, then tumbled by 57.9% to $174.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $174.1 million, $242.5 million, and $305.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.